MCID: MLG108
MIFTS: 58

Malignant Melanoma, Somatic malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Skin diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Malignant Melanoma, Somatic

About this section

Aliases & Descriptions for Malignant Melanoma, Somatic:

Name: Malignant Melanoma, Somatic 49 22
Familial Melanoma 10 12 51
Familial Atypical Multiple Mole Melanoma Syndrome 22 51
Melanoma, Cutaneous Malignant, 1 11 24
Cutaneous Melanoma 22 65
Familial Atypical Multiple Mole Melanoma-Pancreatic Carcinoma Syndrome 51
Familial Atypical Multiple Mole-Melanoma 65
Familial Atypical Mole Melanoma Syndrome 65
Familial Atypical Multiple Mole Melanoma 47
Melanoma-Pancreatic Cancer Syndrome 51
Familial Dysplastic Nevus Syndrome 51
Familial Atypical Mole Syndrome 51
Familial Clark Nevus Syndrome 51
 
Melanoma, Malignant, Somatic 11
Cutaneous Malignant Melanoma 22
Dysplastic Nevus Syndrome 22
Hereditary Melanoma 65
Melanoma, Familial 45
B-K Mole Syndrome 51
Famm-Pc Syndrome 51
Dysplastic Nevus 65
Fammm Syndrome 51
Melanoma 65
Fammm 22
Cmm 22

Characteristics:

Orphanet epidemiological data:

51
familial melanoma:
Inheritance: Autosomal dominant,Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: Adult
familial atypical multiple mole melanoma syndrome:
Inheritance: Autosomal dominant

HPO:

61
malignant melanoma, somatic:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 155600
Disease Ontology10 DOID:6846
NCIt42 C8498
Orphanet51 618, 404560
ICD10 via Orphanet28 C43, D22.9
UMLS65 C1512419, C2314896, C0205748

Summaries for Malignant Melanoma, Somatic

About this section
OMIM:49 Malignant melanoma is a neoplasm of pigment-producing cells called melanocytes that occurs most often in the skin, but... (155600) more...

MalaCards based summary: Malignant Melanoma, Somatic, also known as familial melanoma, is related to glioma and cdk4-related cutaneous malignant melanoma, and has symptoms including melanoma, dry skin and freckling. An important gene associated with Malignant Melanoma, Somatic is CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A), and among its related pathways are Telomere Extension by Telomerase and Bladder cancer. The drugs temozolomide and carmustine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and breast, and related mouse phenotypes are digestive/alimentary and vision/eye.

Related Diseases for Malignant Melanoma, Somatic

About this section

Diseases related to Malignant Melanoma, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 185)
idRelated DiseaseScoreTop Affiliating Genes
1glioma30.0CDK4, CDKN2A, MGMT, PTEN, TP53
2cdk4-related cutaneous malignant melanoma12.5
3cdkn2a-related cutaneous malignant melanoma12.5
4pot1-related susceptibility to cutaneous malignant melanoma12.5
5pancreatic cancer/melanoma syndrome12.2
6melanoma, cutaneous malignant 812.0
7melanoma, cutaneous malignant, 612.0
8mirror movements 111.9
9melanoma, cutaneous malignant, 211.8
10melanoma, cutaneous malignant, 911.6
11melanoma, cutaneous malignant, 511.6
12melanoma, cutaneous malignant, 311.5
13atypical mole syndrome11.5
14primary malignant melanoma of the cervix10.6CDKN2A, PTEN
15angiolipoma10.6CDK4, CDKN2A
16autosomal dominant medullary cystic kidney disease with hyperuricemia10.6CDKN2A, PTEN
17autosomal dominant charcot-marie-tooth disease type 2a210.5CDK4, CDKN2A, PTEN
18hepatic osteogenic sarcoma10.5CDKN2A, PTEN, TERT
19mitral valve stenosis10.5BAP1, CDKN2A, MC1R
20spinal cord astrocytoma10.5CDKN2A, TP53
21vesicoureteral reflux10.5CDKN2A, MITF, PTEN
22anaplastic plasmacytoma10.5CDKN2A, MGMT, POT1
23deep leiomyoma10.5CDKN2A, TP53
24bowing of legs, anterior with dwarfism10.5CDKN2A, TERT
25splenogonadal fusion limb defects micrognatia10.5CDKN2A, TP53
26basaloid squamous cell carcinoma10.5CDKN2A, TP53
27chronic rhinitis10.5CDKN2A, TP53
28cervical verrucous carcinoma10.5CDKN2A, PTEN, TP53
29benign mesenchymoma10.5CDKN2A, PTEN, TP53
30childhood pilocytic astrocytoma10.5CDKN2A, PTEN, TP53
31anal paget's disease10.5CDKN2A, CDKN2B, TP53
32ovary neuroendocrine neoplasm10.5PTEN, TP53
33malignant epithelial mesothelioma10.5BAP1, CDKN2A
34spondyloepimetaphyseal dysplasia, sponastrime type10.4PTEN, STK11, TP53
35tracheal lymphoma10.4CDKN2A, PTEN, TP53
36pleomorphic xanthoastrocytoma10.4CDK4, CDKN2A, MGMT, PTEN
37bleeding disorder, platelet-type, 1310.4PTEN, STK11, TP53
38myxoid chondrosarcoma10.4CDK4, CDKN2A
39soft tissue sarcoma childhood10.4MGMT, PTEN, TP53
40familial short qt syndrome10.4BAP1, CDKN2A, TP53
41hypothalamic disease10.4CDKN2A, PTEN, TP53
42fallopian tube carcinosarcoma10.4CDK4, CDKN2A, TP53
43childhood cerebral astrocytoma10.4PTEN, TERT, TP53
44bacterial vaginosis10.4CDK4, CDKN2A, TP53
45adult astrocytic tumour10.4MGMT, PTEN, TP53
46renal pelvis squamous cell carcinoma10.4CDK6, CDKN2A, TP53
47hartnup disorder10.4CDKN2A, STK11, TP53
48tenosynovitis of foot and ankle10.4CDKN2A, PTEN, TP53
49intracystic papillary adenoma10.4CDK4, TP53
50myotonia congenita10.4CDKN2A, TP53

Graphical network of the top 20 diseases related to Malignant Melanoma, Somatic:



Diseases related to malignant melanoma, somatic

Symptoms for Malignant Melanoma, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

155600

Clinical features from OMIM:

155600

Symptoms:

 51 (show all 12)
  • capillary hemangioma/nevus/naevus flammeus/port-wine stain
  • melanoma
  • dry/squaly skin/exfoliation
  • excessive freckling
  • hair and scalp anomalies
  • anomalies of the lymphatic system
  • retinopathy
  • extrapyramidal syndrome
  • estomach/gastric neoplasm/tumor/carcinoma/cancer
  • pancreatic/pancreas neoplasm/tumor/carcinoma/cancer
  • breast neoplasm/tumor/carcinoma/cancer
  • autosomal dominant inheritance

HPO human phenotypes related to Malignant Melanoma, Somatic:

(show all 15)
id Description Frequency HPO Source Accession
1 melanoma hallmark (90%) HP:0002861
2 dry skin typical (50%) HP:0000958
3 freckling typical (50%) HP:0001480
4 abnormality of the lymphatic system typical (50%) HP:0100763
5 retinopathy occasional (7.5%) HP:0000488
6 abnormality of extrapyramidal motor function occasional (7.5%) HP:0002071
7 neoplasm of the pancreas occasional (7.5%) HP:0002894
8 neoplasm of the stomach occasional (7.5%) HP:0006753
9 neoplasm of the breast occasional (7.5%) HP:0100013
10 cutaneous melanoma HP:0012056
11 intraocular melanoma HP:0007716
12 atypical nevi in non-sun exposed areas HP:0001074
13 atypical nevi (>5mm with irregular edge and pigmentation) HP:0001062
14 numerous nevi HP:0001054
15 abnormality of the eye HP:0000478

Drugs & Therapeutics for Malignant Melanoma, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Mekinist15 41 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
FDA Label: Mekinist
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Indications and Usage:15 MEKINIST is a kinase inhibitor indicated as a single agent and incombination with dabrafenib for the treatment of patients with unresectable ormetastatic melanoma with BRAF V600E or V600K mutations as detected byan FDA-approved test. The use in combination is based on the demonstrationof durable response rate. Improvement in disease-related symptoms or overallsurvival has not been demonstrated for MEKINIST in combination withdabrafenib. (1, 14.1)Limitation of use: MEKINIST as a single agent is not indicated for treatmentof patients who have received prior BRAF-inhibitor therapy. (1)
DrugBank Targets:13 1. Dual specificity mitogen-activated protein kinase kinase 1;2. Dual specificity mitogen-activated protein kinase kinase 2
Mechanism of Action:15 
Target: mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase
Action: inhibitor
FDA: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1(MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins areupstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotescellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAFpathway which includes MEK1 and MEK2. Trametinib inhibits BRAF V600 mutation-positivemelanoma cell growth in vitro and in vivo.Trametinib and dabrafenib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.

Drugs for Malignant Melanoma, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 97)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Dermatologic AgentsPhase 44555
2
AldesleukinapprovedPhase 3, Phase 1, Phase 238785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
3
PaclitaxelapprovedPhase 3, Phase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
4
CisplatinapprovedPhase 3, Phase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
5
CarboplatinapprovedPhase 3, Phase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
6
Dacarbazineapproved, investigationalPhase 3, Phase 1, Phase 24114342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
7
Sorafenibapproved, investigationalPhase 3671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
8
MelphalanapprovedPhase 3685148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
Levofalan
 
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan Hydrochloride
Melphalan [USAN:INN:BAN:JAN]
Melphalan hydrochloride
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
9
MechlorethamineapprovedPhase 330951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
10
VinblastineapprovedPhase 3230865-21-413342, 241903
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC-20335
AC1L21JC
AC1L68D2
AC1MXZJ2
BIDD:PXR0201
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
Bio-0111
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
 
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NCI-C04842
NCI60_004200
NChemBio.2007.10-comp22
NDC 0002-1452-01
NSC 47842
Neuro_000020
Nincaluicolflastine
Rozevin
SPBio_000680
STOCK1N-38480
Spectrum2_000890
Spectrum3_001994
UNII-5V9KLZ54CY
VLB
VR-8
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [DCIT]
Vinblastina [Dcit]
Vinblastine
Vinblastine (INN)
Vinblastine Sulfate
Vinblastine [INN:BAN]
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
nchembio873-comp22
vinblastine
11PembrolizumabapprovedPhase 32881374853-91-4
12
DabrafenibapprovedPhase 3, Phase 1, Phase 27044462760, 44516822
Synonyms:
BRAF inhibitor GSK2118436
Dabrafenib
Dabrafenib Mesylate
 
GSK2118436
GSK2118436a
Tafinlar
dabrafenib
13
TrametinibapprovedPhase 3, Phase 1, Phase 2111871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
14
NivolumabapprovedPhase 3, Phase 2198946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
15
XylometazolineapprovedPhase 366526-36-35709
Synonyms:
 
Balminil
Xylomethazoline
16
Folic Acidapproved, nutraceuticalPhase 3292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
17
Niacinapproved, investigational, nutraceuticalPhase 336159-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Niaspan
Niaspan ER
Nicacid
Nicamin
 
Nicangin
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
18
FotemustineexperimentalPhase 3, Phase 21046936889
Synonyms:
(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
 
Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
Fotemustina
Fotemustinum
19VitaminsPhase 33857
20Antiviral AgentsPhase 3, Phase 28071
21lenograstimPhase 31134
22
Erlotinib HydrochloridePhase 3781183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
23Interleukin-2Phase 3, Phase 1487
24interferonsPhase 3, Phase 21930
25Vitamin B ComplexPhase 32847
26Interferon-alphaPhase 3, Phase 21028
27Anti-Infective AgentsPhase 3, Phase 217220
28Nicotinic AcidsPhase 3361
29AntibodiesPhase 3, Phase 24477
30Antibodies, MonoclonalPhase 3, Phase 22413
31Immunosuppressive AgentsPhase 3, Phase 210422
32Immunologic FactorsPhase 3, Phase 218483
33Alkylating AgentsPhase 3, Phase 1, Phase 23582
34Antineoplastic Agents, AlkylatingPhase 3, Phase 1, Phase 23406
35ImmunoglobulinsPhase 3, Phase 24477
36VaccinesPhase 3, Phase 16085
37Protein Kinase InhibitorsPhase 3, Phase 2, Phase 13162
38Trace ElementsPhase 33900
39MicronutrientsPhase 33901
40Antineoplastic Agents, PhytogenicPhase 3, Phase 24294
41Albumin-Bound PaclitaxelPhase 3, Phase 22621
42Antimitotic AgentsPhase 3, Phase 24296
43Tubulin ModulatorsPhase 3, Phase 24279
44Vitamin B9NutraceuticalPhase 32924
45phenylalanineNutraceuticalPhase 3145
46
Nicotinamideexperimental, NutraceuticalPhase 335398-92-0936
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
37321-14-5
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC-907/25014114
AC1L1ACZ
AC1Q4ZFV
AI3-02906
Acid amide
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra Brand of Niacinamide
Austrovit PP
B 3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin Amide
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
Hansamid
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
LS-2051
MLS000069714
Mediatric
Merck Brand of Niacinamide
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
NCGC00093354-03
NCGC00093354-04
NSC 13128
NSC13128
NSC27452
Nandervit-N
Niacevit
Niacinamide
Niacinamide (USP)
Niacinamide Astra Brand
Niacinamide Jenapharm Brand
Niacinamide Merck Brand
 
Niacinamide Pharmagenix Brand
Niacinamide [USAN]
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid Jenapharm
Nicotinsaureamid [German]
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
PP-Faktor
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix Brand of Niacinamide
Propamine A
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
SGCUT00176
SMR000058212
Savacotyl
UNII-25X51I8RD4
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin B 3
Vitamin B3
Vitamin H1
Vitamin PP
WLN: T6NJ CVZ
Witamina PP
ZINC00005878
b-Pyridinecarboxamide
beta-Pyridinecarboxamide
bmse000281
m-(Aminocarbonyl)pyridine
nchembio.154-comp4
nchembio.73-comp6
niacin - Vitamin B3
niacinamide
nicotinamide
pyridine-3-carboxamide
to_000073
vitamin PP
47FolateNutraceuticalPhase 32924
48Vitamin B3NutraceuticalPhase 3361
49
Temozolomideapproved, investigationalPhase 266285622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
50
Dasatinibapproved, investigationalPhase 1, Phase 2268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1

Interventional clinical trials:

(show top 50)    (show all 93)
idNameStatusNCT IDPhase
1Assessment and Tracking of Long-term Alefacept SafetyTerminatedNCT00454701Phase 4
2Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or LegCompletedNCT00003789Phase 3
3MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3
4Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3
5Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic MelanomaCompletedNCT00003027Phase 3
6ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerCompletedNCT01360554Phase 3
7Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryRecruitingNCT01274338Phase 3
8High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryRecruitingNCT02506153Phase 3
9Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaRecruitingNCT02224781Phase 3
10Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryRecruitingNCT02339571Phase 2, Phase 3
11Thymosin-α1 in Cancer-Related FatigueRecruitingNCT02127268Phase 3
12A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisRecruitingNCT02460068Phase 3
13Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)Active, not recruitingNCT02388906Phase 3
14High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaTerminatedNCT00003641Phase 3
15Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in MelanomaTerminatedNCT00522834Phase 3
16Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant MelanomaCompletedNCT00256282Phase 2
17A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852)CompletedNCT01174238Phase 2
18Disulfiram in Patients With Metastatic MelanomaCompletedNCT00256230Phase 1, Phase 2
19A Phase I/II Study of Dasatinib and DacarbazineCompletedNCT00597038Phase 1, Phase 2
20Interferon Alfa and Thalidomide in Treating Patients With Stage IV MelanomaCompletedNCT00026520Phase 2
21S9804: Vinorelbine in Treating Patients With Stage IV MelanomaCompletedNCT00003828Phase 2
22Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by SurgeryCompletedNCT00626405Phase 2
23Lovastatin in Treating Patients At High Risk of MelanomaCompletedNCT00462280Phase 2
24Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous LeukemiaCompletedNCT00001144Phase 2
25Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2
26A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic MelanomaCompletedNCT00304525Phase 2
27A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT01654692Phase 2
28Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant MelanomaRecruitingNCT01321437Phase 2
29Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV MelanomaRecruitingNCT01107665Phase 2
30PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCERRecruitingNCT01037790Phase 2
31Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryRecruitingNCT01989585Phase 1, Phase 2
32Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryRecruitingNCT02196181Phase 2
33Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryRecruitingNCT00700882Phase 2
34Pilot Study Evaluating the Efficacy and Safety of Metformin in MelanomaRecruitingNCT01840007Phase 2
35Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryRecruitingNCT01950390Phase 2
36Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II StudyRecruitingNCT02424916Phase 1, Phase 2
37Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester DiseaseRecruitingNCT02281760Phase 2
38Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant MelanomaActive, not recruitingNCT00976573Phase 2
39Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the EyeActive, not recruitingNCT01835145Phase 2
40Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryActive, not recruitingNCT01134614Phase 2
41Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryActive, not recruitingNCT01708941Phase 2
42Trametinib With GSK2141795 in BRAF Wild-type MelanomaActive, not recruitingNCT01941927Phase 2
43Randomized Trial of ATN-224 and Temozolomide in Advanced MelanomaActive, not recruitingNCT00383851Phase 2
44S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain MetastasesTerminatedNCT00003911Phase 2
45Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
46131-I-TM-601 Study in Adults With Solid TumorsCompletedNCT00379132Phase 1
47Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic MelanomaRecruitingNCT02117362Phase 1
48Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic TherapyTerminatedNCT00571116Phase 1
49BAY1238097, First in ManTerminatedNCT02369029Phase 1
50Genetic Analysis of Familial MelanomaCompletedNCT00339404

Search NIH Clinical Center for Malignant Melanoma, Somatic

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Malignant Melanoma, Somatic

About this section

Genetic tests related to Malignant Melanoma, Somatic:

id Genetic test Affiliating Genes
1 Cutaneous Malignant Melanoma22 MC1R
2 Malignant Melanoma, Somatic22 BRAF, KIT, NRAS, PTEN, CDKN2A

Anatomical Context for Malignant Melanoma, Somatic

About this section

MalaCards organs/tissues related to Malignant Melanoma, Somatic:

33
Skin, Eye, Breast, Lung, Pancreas, Testes, Brain

Animal Models for Malignant Melanoma, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Malignant Melanoma, Somatic:

38 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053819.6ACD, CDK4, CDKN2A, PTEN, STK11, TERT
2MP:00053919.4ASIP, CDK4, CDKN2A, CDKN2D, MITF, PTEN
3MP:00053779.3ACD, ASIP, CDKN2D, MC1R, MITF, TP53
4MP:00053679.2ACD, ANK1, ASIP, CDK4, CDKN2B, PTEN
5MP:00053709.2ANK1, ASIP, CDK4, CDK6, CDKN2A, PTEN
6MP:00030129.2BAP1, CDKN2A, CDKN2B, MC1R, MGMT, MITF
7MP:00053809.1ASIP, BAP1, CDK4, CDK6, CDKN2A, MITF
8MP:00053699.1ANK1, BAP1, CDK4, CDK6, CDKN2A, CDKN2D
9MP:00011869.1ACD, ANK1, ASIP, CDK4, CDKN2A, MC1R
10MP:00053858.8ANK1, ASIP, BAP1, CDK4, CDK6, CDKN2A
11MP:00053868.8ACD, ANK1, ASIP, CDK4, CDKN2A, CDKN2D
12MP:00107718.7ACD, ANK1, ASIP, CDK4, CDKN2A, CDKN2B
13MP:00036318.7ANK1, ASIP, CDK4, CDKN2A, CDKN2D, MITF
14MP:00053898.5ACD, ANK1, CDK4, CDK6, CDKN2A, CDKN2B
15MP:00020068.3ACD, ASIP, BAP1, CDK4, CDK6, CDKN2A
16MP:00053798.3ACD, ANK1, ASIP, CDK4, CDK6, CDKN2A
17MP:00053978.1ANK1, ASIP, BAP1, CDK4, CDK6, CDKN2A
18MP:00053878.1ANK1, ASIP, BAP1, CDK4, CDK6, CDKN2A
19MP:00053768.0ACD, ANK1, ASIP, BAP1, CDK4, CDKN2A
20MP:00053787.9ACD, ANK1, ASIP, BAP1, CDK4, CDK6
21MP:00053847.7ACD, ASIP, BAP1, CDK4, CDK6, CDKN2A
22MP:00107687.3ACD, ANK1, ASIP, BAP1, CDK4, CDK6

Publications for Malignant Melanoma, Somatic

About this section

Variations for Malignant Melanoma, Somatic

About this section

Clinvar genetic disease variations for Malignant Melanoma, Somatic:

5
id Gene Variation Type Significance SNP ID Assembly Location
1STK11NM_000455.4(STK11): c.580G> T (p.Asp194Tyr)single nucleotide variantPathogenicrs121913315GRCh37Chr 19, 1220487: 1220487
2STK11NM_000455.4(STK11): c.508C> T (p.Gln170Ter)single nucleotide variantPathogenicrs121913323GRCh37Chr 19, 1220415: 1220415
3STK11NM_000455.4(STK11): c.145T> G (p.Tyr49Asp)single nucleotide variantPathogenicrs137853080GRCh37Chr 19, 1207057: 1207057
4STK11NM_000455.4(STK11): c.403G> C (p.Gly135Arg)single nucleotide variantPathogenicrs137853081GRCh37Chr 19, 1219351: 1219351
5CDKN2ANM_000077.4(CDKN2A): c.106dupG (p.Ala36Glyfs)duplicationPathogenicrs398123152GRCh37Chr 9, 21974721: 21974721
6CDKN2ANM_000077.4(CDKN2A): c.226_244del19 (p.Ala76Cysfs)deletionPathogenic, risk factorrs587776716GRCh37Chr 9, 21971114: 21971132

Cosmic variations for Malignant Melanoma, Somatic:

7 (show all 39)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM27639BRAFskin,ear,malignant melanoma,NS3
2COSM27639BRAFskin,ear,malignant melanoma,NS3
3COSM27639BRAFskin,ear,malignant melanoma,NS3
4COSM478BRAFskin,ear,malignant melanoma,NS3
5COSM478BRAFskin,ear,malignant melanoma,NS3
6COSM478BRAFskin,ear,malignant melanoma,NS3
7COSM1125BRAFskin,ear,malignant melanoma,NS3
8COSM1125BRAFskin,ear,malignant melanoma,NS3
9COSM471BRAFskin,ear,malignant melanoma,NS3
10COSM471BRAFskin,ear,malignant melanoma,NS3
11COSM476BRAFskin,ear,malignant melanoma,NS3
12COSM476BRAFskin,ear,malignant melanoma,NS3
13COSM1125BRAFskin,ear,malignant melanoma,NS3
14COSM476BRAFskin,ear,malignant melanoma,NS3
15COSM471BRAFskin,ear,malignant melanoma,NS3
16COSM109660GRIN2Askin,ear,malignant melanoma,NS3
17COSM109660GRIN2Askin,ear,malignant melanoma,NS3
18COSM109660GRIN2Askin,ear,malignant melanoma,NS3
19COSM110485GRIN2Askin,ear,malignant melanoma,NS3
20COSM110485GRIN2Askin,ear,malignant melanoma,NS3
21COSM106626GRIN2Askin,ear,malignant melanoma,NS3
22COSM106626GRIN2Askin,ear,malignant melanoma,NS3
23COSM110485GRIN2Askin,ear,malignant melanoma,NS3
24COSM106626GRIN2Askin,ear,malignant melanoma,NS3
25COSM580NRASskin,ear,malignant melanoma,NS3
26COSM580NRASskin,ear,malignant melanoma,NS3
27COSM580NRASskin,ear,malignant melanoma,NS3
28COSM580NRASskin,ear,malignant melanoma,NS3
29COSM580NRASskin,ear,malignant melanoma,NS3
30COSM580NRASskin,ear,malignant melanoma,NS3
31COSM141892CNR1skin,ear,malignant melanoma,NS3
32COSM141892CNR1skin,ear,malignant melanoma,NS3
33COSM141892CNR1skin,ear,malignant melanoma,NS3
34COSM141856CHRM3skin,ear,malignant melanoma,NS3
35COSM141856CHRM3skin,ear,malignant melanoma,NS3
36COSM141856CHRM3skin,ear,malignant melanoma,NS3
37COSM1651647KITskin,eye,malignant melanoma,NS3
38COSM1651647KITskin,eye,malignant melanoma,NS3
39COSM1651647KITskin,eye,malignant melanoma,NS3

Expression for genes affiliated with Malignant Melanoma, Somatic

About this section
Search GEO for disease gene expression data for Malignant Melanoma, Somatic.

Pathways for genes affiliated with Malignant Melanoma, Somatic

About this section

Pathways related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.0POT1, TERF2IP, TERT
29.9CDK4, CDKN2A, TP53
39.9CDK4, TERT, TP53
4
Show member pathways
9.8CDKN2B, CDKN2D, PTEN, STK11
59.8CDK4, CDK6, TP53
69.8CDK4, CDK6, TP53
7
Show member pathways
9.8CDK4, CDK6, CDKN2A, CDKN2B
8
Show member pathways
9.8ACD, CDK4, POT1, TERF2IP
99.8CDK4, PTEN, STK11, TP53
109.8ACD, POT1, TERF2IP, TERT
11
Show member pathways
9.7CDK4, CDK6, CDKN2A, TP53
129.7CDK4, CDK6, STK11, TP53
13
Show member pathways
9.6ASIP, MC1R, MITF, TP53
149.6CDK4, CDKN2B, PTEN, STK11, TP53
159.6CDK4, CDKN2A, CDKN2B, TERT, TP53
16
Show member pathways
9.5CDK4, CDK6, CDKN2A, PTEN, TP53
179.5CDK4, CDK6, PTEN, STK11, TP53
189.5CDK4, CDK6, CDKN2A, CDKN2B, TP53
199.5CDK4, CDK6, CDKN2B, PTEN, TP53
209.4CDK4, CDK6, CDKN2A, MGMT, PTEN, TP53
219.3CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D, TP53
22
Show member pathways
9.3CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D, TP53
23
Show member pathways
9.3CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D, TP53
249.3CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D, TP53
25
Show member pathways
9.2CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D, TP53
26
Show member pathways
9.2CDK4, CDK6, CDKN2A, CDKN2B, MITF, PTEN
279.2CDK4, CDK6, CDKN2A, CDKN2B, MITF, PTEN
28
Show member pathways
8.8ACD, CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D
29
Show member pathways
8.6ACD, CDK4, CDK6, CDKN2A, CDKN2B, CDKN2D

GO Terms for genes affiliated with Malignant Melanoma, Somatic

About this section

Cellular components related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1PML bodyGO:00166059.9PTEN, TERT, TP53

Biological processes related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1telomere assemblyGO:003220210.7ACD, POT1
2intrinsic apoptotic signaling pathway by p53 class mediatorGO:007233210.6STK11, TP53
3positive regulation of telomerase activityGO:005197310.6ACD, POT1
4regulation of protein stabilityGO:003164710.5CDKN2A, PTEN, TERT
5establishment of protein localization to telomereGO:007020010.5POT1, TERT
6negative regulation of cellular senescenceGO:200077310.5CDK6, TERT
7cell cycle arrestGO:000705010.3CDK6, CDKN2A, TP53
8negative regulation of phosphorylationGO:004232610.3CDKN2A, CDKN2B, CDKN2D
9negative regulation of protein serine/threonine kinase activityGO:007190110.3CDKN2B, CDKN2D
10negative regulation of G1/S transition of mitotic cell cycleGO:200013410.2CDKN2B, PTEN
11protein sumoylationGO:001692510.2CDKN2A, MITF, TP53
12dentate gyrus developmentGO:002154210.1CDK6, PTEN
13negative regulation of cell growthGO:003030810.1CDKN2A, STK11, TP53
14replicative senescenceGO:009039910.0CDKN2A, TERT, TP53
15regulation of cell cycleGO:00517269.7BAP1, CDK4, PTEN
16positive regulation of transcription from RNA polymerase II promoterGO:00459449.2CDKN2A, CDKN2B, MC1R, MITF, NCOA6, TP53

Sources for Malignant Melanoma, Somatic

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet